Phase II study examining the biological efficacy of intratumoral INGN 241 (Ad-mda7) administration in patients with in transit melanoma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs INGN 241 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Nov 2005 New trial record.